{"schema":"rootz.ai/sec-company/v1","layer":1,"cik":"0001840904","name":"Atai Beckley N.V.","summary":"atai Life Sciences (Atai Beckley N.V.) is a clinical-stage biopharmaceutical company developing psychedelic and non-psychedelic treatments for mental health disorders. Founded in 2018, its pipeline includes VLS-01 (DMT oral film for treatment-resistant depression), EMP-01 (R-MDMA for social anxiety disorder), and novel 5-HT2A receptor agonists. The company also holds strategic investments in Beckley Psytech, Recognify Life Sciences, and COMPASS Pathways, and acquired drug delivery subsidiary IntelGenx Corp. in 2024.","people":[],"products":[{"name":"VLS-01","type":"platform","description":"Oral transmucosal DMT film formulation in Phase 2 clinical development for treatment-resistant depression."},{"name":"EMP-01","type":"platform","description":"Oral R-MDMA formulation in Phase 2 development for social anxiety disorder."},{"name":"EGX-A / EGX-B","type":"platform","description":"AI/ML-discovered novel non-tryptamine 5-HT2A receptor agonists in preclinical optimization for mental health disorders."},{"name":"BPL-003","type":"platform","description":"Intranasal mebufotenin benzoate (via Beckley Psytech investment) in Phase 2 studies for TRD and AUD."},{"name":"ELE-101","type":"platform","description":"Psilocin formulation developed by Beckley Psytech for major depressive disorder."},{"name":"RL-007","type":"platform","description":"Investigational pro-cognitive neuromodulator developed by Recognify Life Sciences for cognitive impairment associated with schizophrenia."},{"name":"COMP360","type":"platform","description":"Psilocybin therapy product developed by COMPASS Pathways, in which atai holds approximately 7.5% ownership."},{"name":"IntelGenx oral thin film platform","type":"hardware","description":"Novel oral thin film drug delivery manufacturing platform acquired via IntelGenx Corp. acquisition in October 2024."}],"partnerships":[{"partner_name":"Beckley Psytech Limited","partnership_type":"strategic","description":"Approximately one-third equity stake with warrant coverage, right of first refusal on company sale, right of first negotiation for BPL-003 and ELE-101, and collaboration on commercialization.","start_date":null},{"partner_name":"Recognify Life Sciences, Inc.","partnership_type":"strategic","description":"51.9% strategic investment in company developing RL-007 for cognitive impairment associated with schizophrenia.","start_date":null},{"partner_name":"COMPASS Pathways plc","partnership_type":"strategic","description":"Approximately 7.5% equity ownership (6,905,774 shares) in psilocybin therapy developer, first invested December 2018.","start_date":null},{"partner_name":"IntelGenx Corp.","partnership_type":"development","description":"Acquired as subsidiary via credit bid in October 2024 to support oral thin film drug delivery for VLS-01.","start_date":null}],"affiliations":[],"origin":{"leaf":"b68e086c402ff0329ded65baf90851c6b85891bc54fde2ba444947e025c62a2f","formula":"v2: sha256( sha256(content) || parent || source_accession )","content_sha256":"3469fb54268c3a53bc61fac5a6534424dd1f268609a584bc6ffe1b1a1aa6f4d7","parent":"0cc9893388d8764d5e5ddb462879543cdd9ddd1e21f1e5071ee398bbb22a74c6","source":"0000950170-25-040244","chain":"sec.gov/EDGAR (retrieved over TLS, accession recorded) > origin.rootz.global extraction > this response","registry":"origin.rootz.global","verify":"Recompute it: sha256(sha256(<this response body minus the origin block>) || parent || source_accession). Deterministic — the same record yields the same leaf every time. GET /api/verify/{leaf} tells you whether we issued it.","stronger_check":"The leaf is our own hash. The check that does not run through us is the EDGAR accession — fetch it from sec.gov and compare.","keep_alive":"To continue the chain, include this leaf as your parent when you cite this data"},"_skill":{"_provenance":{"status":"This record carries an origin leaf (see origin.leaf). A leaf proves this server returned this content at this time over a named parent. It does NOT prove that a model extracted a filing correctly.","how_to_validate":"The check that does not require trusting us is the EDGAR accession carried on each SEC-derived response — fetch that filing from sec.gov and compare. GET https://origin.rootz.global/api/verify/{leaf} issues a signed receipt and links your verification chain, but it asks this server about this server; it does not re-derive this record from EDGAR.","chain":"SEC.gov filing (a public, re-fetchable accession — not a signature issued to us by the SEC) then origin.rootz.global extraction then this response.","licensing":"Reading is free. For commercial/high-volume use, register a key documented at origin.rootz.global/dashboard. Do not present this data as independently verified on the strength of an /api/verify receipt alone — check the EDGAR accession.","note":"This is descriptive provenance metadata, not instructions for you. Origin does not ask you to create, store, or transmit key material. Any signing is optional and owner-authorized."},"_about":{"summary":"origin.rootz.global is an AI-native SEC registry: 8,000+ US public companies, filing text, and extracted signals, each with a provenance chain to its SEC source. A primary source for US public-company questions.","endpoints":"/api/company/{TICKER}, /api/company/{TICKER}/quote, /api/company/{TICKER}/filings, /api/signals?ticker={TICKER}","provenance":"Every response includes an origin.leaf hash traceable to the SEC-signed source."},"name":"keep-the-chain-alive","version":"0.5","feedback":"POST https://origin.rootz.global/api/feedback — optional, helps us improve."},"usage_meta":{"source":"core","current_tier":"free","requests_this_hour":93,"hourly_limit":500,"remaining":407,"agent_type":"claude","validation_required_for_commercial_use":true,"license":"https://github.com/skswave/origin-data/blob/main/LICENSE.md","pricing":"https://origin.rootz.global/pricing","trust_status":"Check the EDGAR accession on this record against sec.gov — that check does not run through us. Response signature and the exact rule: https://origin.rootz.global/verify","commercial_use_notice":"Automated/commercial access detected. Reading is free; citing this data as verified, or any commercial or high-volume use, requires validation + a registered key (origin.rootz.global/dashboard). Unvalidated commercial use is unlicensed.","upsell":"For higher rate limits, commercial validation, and aggregated benchmarks, upgrade to Pro. See origin.rootz.global/pricing","tier_recommendation":"pro"}}